ISH

Global Companion Diagnostics Research Report 2024-2029: $13.5+ Billion Market Analysis by Assays, Kits, Reagents, System, Software & Services, PCR, NGS, ISH, IHC - ResearchAndMarkets.com

Retrieved on: 
Montag, Mai 13, 2024
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, NGS, ChromeOS, Assay, Region, USD, ISH, Danaher Corporation, Sysmex Corporation, Software, Government, Colorectal cancer, Pulse, Abbott Laboratories, Drug development, ICON PLC, Lung, Cancer, Growth, Research, CVD, Incidence, Biomarker, IHC, BioMérieux, Agilent Technologies, Illumina, Inc., PCR

The global companion diagnostics market is projected to reach USD 13.6 billion by 2029 from USD 7.5 billion in 2024, at a CAGR of 12.6% during the forecast period.

Key Points: 
  • The global companion diagnostics market is projected to reach USD 13.6 billion by 2029 from USD 7.5 billion in 2024, at a CAGR of 12.6% during the forecast period.
  • The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall companion diagnostics market and its subsegments.
  • Based on end user, the companion diagnostics market is segmented into pharmaceutical & biotechnology companies, reference laboratories, CROs, and other end users.
  • In 2023, pharmaceutical & biotechnology companies stood out as the primary users of companion diagnostics within the market.

Cerebrum Announces Integration Support with Sakura Finetek Products

Retrieved on: 
Montag, Mai 13, 2024
LIS, Microtome, Health, ISH, Marketing, Cerebrum, Laboratory information management system, TAT, Dermatology, Pathology, IHC, Communication, ASCP, Laboratory, HL7

PHOENIX, May 13, 2024 /PRNewswire-PRWeb/ -- Cerebrum™, a leading provider of Laboratory Information System (LIS) software, announced new capabilities and a collaboration with Sakura Finetek USA to support anatomic pathology labs increasing productivity and overall workflow. Cerebrum's LABdivus® now supports complete integration with Sakura Finetek USA's Tissue-Tek AutoTEC® a120 Automated Embedding System and Tissue-Tek Genie® Advanced Staining System.

Key Points: 
  • Cerebrum™ - Sakura Finetek integration saves customers time, reduces errors
    PHOENIX, May 13, 2024 /PRNewswire-PRWeb/ -- Cerebrum™, a leading provider of Laboratory Information System (LIS) software, announced new capabilities and a collaboration with Sakura Finetek USA to support anatomic pathology labs increasing productivity and overall workflow.
  • Cerebrum's LABdivus® now supports complete integration with Sakura Finetek USA's Tissue-Tek AutoTEC® a120 Automated Embedding System and Tissue-Tek Genie® Advanced Staining System.
  • Cerebrum also released Cerebrum Connect™, a configurable middleware program, to connect the Tissue-Tek AutoTEC a120 and Tissue-Tek Genie to alternative laboratory information systems (LIS) through HL7 interfacing.
  • Pricing for Cerebrum Connect can be found on the Cerebrum website, www.cerebrumcorp.com
    "This integration is a game-changer for our lab.

EQS-News: Promising start to the year: Mutares increases net income of the Holding in the first quarter of 2024 thanks to successful exit - expansion into the growth market India initiated

Retrieved on: 
Freitag, Mai 10, 2024
ISH, Goods, HPC, Peugeot, Sale, Investment, Depreciation, Iveco, Retail, EUR, Automotive industry, Growth, Original equipment manufacturer, Restaurant, High, Tax, EFACEC, Classification, KICO, Mobility, Acquisition, Realignment, Adjustment, Film industry

Promising start to the year: Mutares increases net income of the Holding in the first quarter of 2024 thanks to successful exit - expansion into the growth market India initiated

Key Points: 
  • Promising start to the year: Mutares increases net income of the Holding in the first quarter of 2024 thanks to successful exit - expansion into the growth market India initiated
    The issuer is solely responsible for the content of this announcement.
  • At Group level, Mutares generated revenues of EUR 1,346.1 million in the first quarter of 2024 (previous year: EUR 1,108.0 million).
  • The transaction makes a significant contribution to the net income of Mutares Holding in the first quarter of 2024.
  • EBITDA for the segment amounted to EUR -13.5 million in the first quarter of 2024 (previous year: EUR 20.1 million).

ArsenalBio Announces Presentation of Four Abstracts at ASGCT Annual Meeting Highlighting New Mechanisms for Leveraging CAR T Cells to Address Solid Tumor Cancers

Retrieved on: 
Montag, Mai 6, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, ISH, PSMA, CD3, CA9, Payload, CRISPR, SPA, Risk, Tissue, ICT, Abstract, Immunosuppression, Cytokine, Tumor microenvironment, Cell, Research, Primer, Downregulation and upregulation, Engineering, DNA, Science, Gene, Society, Neoplasm, Antigen, Messenger, Information and communications technology, Immune system, Kidney cancer, In situ hybridization, Ovarian cancer, Vaccine

These data highlight the portfolio of solutions ArsenalBio is developing to address unmet need in solid tumor cancers, including those currently being studied as potential treatments for ovarian cancer ( NCT05617755 ) and kidney cancer ( NCT06245915 ).

Key Points: 
  • These data highlight the portfolio of solutions ArsenalBio is developing to address unmet need in solid tumor cancers, including those currently being studied as potential treatments for ovarian cancer ( NCT05617755 ) and kidney cancer ( NCT06245915 ).
  • It integrates an “AND” logic gate designed to limit off-tumor toxicity through a requirement for dual tumor antigen recognition.
  • T cell exhaustion from chronic antigen stimulation and an immunosuppressive tumor microenvironment limits the efficacy of T cell therapies used to treat solid tumors.
  • This research used CRISPR/Cas9-based screening, paired with deep sequencing, to identify intrinsic genetic perturbations that can prevent T cell exhaustion.

Krispy Kreme® Announces Expansion into Germany

Retrieved on: 
Mittwoch, Mai 1, 2024
Retail, Restaurant, Bar, Convenience Store, Food, Beverage, ISH, Krispy Kreme, KFC, News, Pizza Hut, Fast food

Krispy Kreme, Inc. (NASDAQ: DNUT) today announced an agreement with restaurant group ISH Kreme to bring one of the world’s most loved sweet treats to Germany.

Key Points: 
  • Krispy Kreme, Inc. (NASDAQ: DNUT) today announced an agreement with restaurant group ISH Kreme to bring one of the world’s most loved sweet treats to Germany.
  • Krispy Kreme® will offer its iconic, fresh doughnuts to German consumers through a network of Krispy Kreme shops starting in Berlin.
  • “We are excited to expand into Germany as it has been a priority market for us, offering substantial growth with more than 3,000 points of access,” said Raphael Duvivier, Krispy Kreme Chief Development Officer.
  • Each Krispy Kreme doughnut is made fresh daily, hand-crafted, and hand-decorated to ensure the melt-in-your-mouth taste that has become synonymous with the brand.

BIO-TECHNE FILES PATENT INFRINGEMENT LAWSUIT AGAINST MOLECULAR INSTRUMENTS

Retrieved on: 
Dienstag, April 23, 2024
ISH, Trial, Investment, Research, Bio-Techne, COMET, Unified Patent Court, Acquisition, Intellectual property, ACD

MINNEAPOLIS, April 23, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced that it has taken legal action in the Unified Patent Court in Europe to halt the infringement of its patented RNAscope® ISH technology by Molecular Instruments, Inc.

Key Points: 
  • Bio-Techne enforces intellectual property for gold standard RNAscope® ISH technology in spatial biology research and clinical applications.
  • RNAscope is the most referenced technology in the industry, with its rapidly growing portfolio of peer-reviewed publications recently surpassing 10,000.
  • In its lawsuit filed in the Unified Patent Court (a pan-European forum for resolving patent disputes), in the Netherlands Local Division of the Court of First Instance in The Hague, Bio-Techne alleges that Molecular Instruments' HCR 3.0 technology infringes ACD's European Patents 1,910,572 and 2,500,439.
  • The lawsuit seeks damages and injunctive relief requiring Molecular Instruments to stop infringing ACD's patents in key European markets.

BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 1, 2024, TO ANNOUNCE THIRD QUARTER FISCAL 2024 FINANCIAL RESULTS

Retrieved on: 
Mittwoch, April 10, 2024
ISH, FDA, Nature, Social media, ELISA, Cytokine, Gene editing, Conference, Research, Workflow, Diagnosis, CDT, Antibody, ACD, Drug discovery

The replay will be available from 11:00 a.m. CDT on Wednesday, May 1, 2024, until 11:00 p.m. CDT on Saturday, June 1, 2024.

Key Points: 
  • The replay will be available from 11:00 a.m. CDT on Wednesday, May 1, 2024, until 11:00 p.m. CDT on Saturday, June 1, 2024.
  • These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment.
  • With thousands of products in its portfolio, Bio-Techne generated over $1.1 billion in net sales in fiscal 2023 and has approximately 3,100 employees worldwide.
  • For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook , LinkedIn , Twitter or YouTube .

YR Media’s Adult ISH Podcast Season 11 Spotlights Young Leaders “Standing Up”

Retrieved on: 
Donnerstag, April 4, 2024
BIPOC, Homelessness, Youth Radio, Culture, Farm, ISH, Indigenous, Radiotopia, Apple Podcasts, Amazon Music, Mental health, Social media, Food, Movement, American Civil Liberties Union, Student, Season, TuneIn, PRX, Music, San Francisco Bay Area, IHeartRadio, Gen, ACLU

Oakland, California, April 04, 2024 (GLOBE NEWSWIRE) -- Adult ISH , the award-winning advice, culture, and storytelling podcast from YR Media and part of the Radiotopia podcast network from PRX, is launching its 11th season with the first of ten episodes dropping Thursday, April 11, 2024.

Key Points: 
  • Oakland, California, April 04, 2024 (GLOBE NEWSWIRE) -- Adult ISH , the award-winning advice, culture, and storytelling podcast from YR Media and part of the Radiotopia podcast network from PRX, is launching its 11th season with the first of ten episodes dropping Thursday, April 11, 2024.
  • What differences are there as a teen versus when you’re a legal adult?
  • “Season 11 is about young people being authentically themselves as they follow their passions.”
    “As YR Media celebrates 30 years of impact – producing audio with aspiring teen and young adult podcasters, journalists, and musicians – I’m excited that Adult ISH will amplify even more of our YR Media students’ voices in this season,” said YR Media CEO Kyra Kyles.
  • Learn more about the podcast here and follow along on social media:

North America Molecular Diagnostics Market Size, Share & Trends Analysis Report 2024-2030: Growing Prevalence of Target Diseases & Increasing External Funding for R&D Fueling Expansion - ResearchAndMarkets.com

Retrieved on: 
Dienstag, März 26, 2024
Health, Biotechnology, Candidiasis, Diagnosis, PCR, MVP, Conditional sentence, Bacterial vaginosis, Prevalence, Infection, Promega, Country, Thermo Fisher Scientific, SME, Tuberculosis, Application, ISH, RT, HIV, Alzheimer's disease, Incidence, Turner syndrome, Cepheid variable, Research, Trichomoniasis, Real-time, Cancer, Death, Parkinson's disease, CDC, QIAGEN, Therapy, USD, Horvitz–Thompson estimator, Helix, DSM-IV codes, Vaccine

Advancements in molecular diagnostic technology enabled the early detection of numerous diseases and reduced the possibility of severe economic & social burdens.

Key Points: 
  • Advancements in molecular diagnostic technology enabled the early detection of numerous diseases and reduced the possibility of severe economic & social burdens.
  • Molecular diagnostics enable early diagnosis of cancer, genetic disorders, and infectious diseases by using PCR, sequencing, & genetic technologies.
  • In addition, the increasing incidence of diseases, such as influenza A & B, is projected to drive market growth.
  • An increase in external funding to conduct clinical studies in molecular diagnostics is anticipated to fuel the market.

BIO-TECHNE RECEIVES CiteAb'S ELISA KIT SUPPLIER OF THE YEAR AND SPATIAL BIOLOGY INNOVATION AWARDS

Retrieved on: 
Montag, April 1, 2024
ISH, Protein Sciences, Education, CiteAb, ELISA, RNA, Antibody, Research, Diagnosis, ACD, Literature, Elisa's

Additionally, Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Biology Division, was named winner of "The Innovation Award" in recognition of its RNAscope™ ISH technology and its role in helping to advance scientific discovery.

Key Points: 
  • Additionally, Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Biology Division, was named winner of "The Innovation Award" in recognition of its RNAscope™ ISH technology and its role in helping to advance scientific discovery.
  • The ELISA Kit Supplier of the Year award is a testament to the depth and breadth of the R&D Systems citation database, which covers reagent data for nearly one million ELISA kit products.
  • CiteAb's Innovation Award recognizes ACD's RNAscope HiPlex12 Flex Kit, which provides greater flexibility to researchers performing in situ spatial detection of target RNA.
  • The Innovation Award given to our ACD brand underscores our Spatial Biology team's dedication to enriching our customers' experiences and prioritizing researchers' needs."